Study: NCT05000216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continue IS (MMF or MPA)
Description: Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continue IS (MTX)
Description: Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continue IS (MTX)
Description: Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continue IS (MTX)
Description: Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continue IS (MTX)
Description: Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continue IS (MTX)
Description: Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Continue IS (B cell depletion therapy)
Description: Participants will continue to take their prescribed immunosuppressive (IS) medications without alterations in schedule and dosing.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Continue IS (B cell depletion therapy)
Description: Participants will continue to take their prescribed immunosuppressive (IS) medications without alterations in schedule and dosing.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Continue IS (B cell depletion therapy)
Description: Participants will continue to take their prescribed immunosuppressive (IS) medications without alterations in schedule and dosing.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Continue IS (B cell depletion therapy)
Description: Participants will continue to take their prescribed immunosuppressive (IS) medications without alterations in schedule and dosing.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Continue IS (B cell depletion therapy)
Description: Participants will continue to take their prescribed immunosuppressive (IS) medications without alterations in schedule and dosing.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent [B.1.351] CoV2 preS dTM-AS03
Description: One dose administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent [B.1.351] CoV2 preS dTM-AS03
Description: One dose administered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent [B.1.351] CoV2 preS dTM-AS03
Description: One dose administered intramuscularly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Withhold IS (MMF or MPA)
Description: Participants withhold their cohort-defining immunosuppressive (IS) medications for management of their autoimmune disease before and after the additional vaccine dose per protocol instructions.